Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease is the major cause of death in patients with diabetes. Current treatment strategies for diabetes rely on lifestyle changes and glucose control to prevent angiopathy and organ failure. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used as an add-on therapy to insulin treatment. Exenatide also has multiple beneficial effects in addition to its hypoglycemic effects, such as preventing hepatic steatosis and protecting against cardiac injury from doxorubicin-induced cardiotoxicity or ischemic reperfusion. However, the mechanisms underlying the cardioprotective effects of exenatide in diabetes have not been fully clarified. To address this issue, we investigated the cardioprotective effects of exenatide in type 1 and type 2 diabetic mice. We found that exenatide simultaneously attenuated reactive oxidative species (ROS) production through increases in the antioxidant enzymes manganese dependent superoxide dismutase (MnSOD) and catalase. Moreover, exenatide decreased tumor protein P53 (p53) expression and prevented cell apoptosis in H9c2 cells. The presence of the catalase inhibitor 3-AT attenuated the effects of exenatide. Overall, the results strongly indicate that exenatide treatment may be protective against the development of diabetic cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., et al. (2013) · Diabetes · doi:10.2337/db12-1025 · Cited by 179
Younce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Koehler, J. A., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., & Drucker, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.005 · Cited by 133 · cited 1×
“A molecular mechanism study of intestinal growth used exenatide (42 μg/kg, twice daily, equal to 10 nmol/kg) as a GLP-1R agonist (36).”
BackgroundSIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114
Wang, D., Sun, H., Song, G., Yang, Y., Zou, X., Han, P., & Li, S. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700941 · Cited by 102
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
Cited by
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91
“In diabetic rodent models, Exendin-4 treatment improved cardiac function and glucose uptake [18].”
BackgroundBalogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Metadata
- Authors
- Ding, W., Chang, W.-G., Guo, X.-C., Liu, Y., Xiao, D.-D., Ding, D., Wang, J.-X., & Zhang, X.-J.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-05
- Volume
- 10
- Pages
- 202-202
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2929823585
- Cited by
- 50
- References
- 8
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart. https://app.cochat.ai/papers/10.3389/fendo.2019.00202
- The paper
- Ding, W., Chang, W.-G., Guo, X.-C., Liu, Y., Xiao, D.-D., Ding, D., Wang, J.-X., & Zhang, X.-J. (2019). Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2019.00202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.